These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6371385)

  • 1. High-dose versus low-dose CMFP regimen in advanced breast cancer.
    Kumar A; Khanna NN; Pant GC; Khanna S
    J Surg Oncol; 1984 Apr; 25(4):300-2. PubMed ID: 6371385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Goodyear M
    J Clin Oncol; 1986 Mar; 4(3):442-4. PubMed ID: 3512787
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
    Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
    Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer.
    Carmo-Pereira J; Costa FO; Henriques E; Carvalho V
    Cancer Chemother Pharmacol; 1986; 17(1):87-90. PubMed ID: 3516431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer.
    Price LA; Hill BT
    Cancer Treat Rev; 1990 Sep; 17(2-3):191-6. PubMed ID: 2272033
    [No Abstract]   [Full Text] [Related]  

  • 6. Five-drug therapy in advanced breast cancer: factors influencing toxicity and response.
    Davis HL; Ramirez G; Ellerby RA; Ansfield FJ
    Cancer; 1974 Aug; 34(2):239-45. PubMed ID: 4852055
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Marschke RF; Ingle JN; Schaid DJ; Krook JE; Mailliard JA; Cullinan SA; Pfeifle DM; Votava HJ; Ebbert LP; Windschitl HE
    Cancer; 1989 May; 63(10):1931-7. PubMed ID: 2649221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
    Bishop JF; Dewar J; Toner GC; Smith J; Tattersall MH; Olver IN; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J; Canetta R
    J Clin Oncol; 1999 Aug; 17(8):2355-64. PubMed ID: 10561297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer.
    Segaloff A; Hankey BF; Carter AC; Escher GC; Ansfield FJ; Talley RW
    Breast Cancer Res Treat; 1985; 5(3):311-9. PubMed ID: 3896353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of metastatic breast cancer].
    Yahalom J; Biran S; Sulkes A
    Harefuah; 1986 Jul; 111(1-2):8-11. PubMed ID: 2430868
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
    Cadman EC; Glick JH; Cross J; Horton J; Taylor SG
    Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
    Cebon JS; Bishop JF; Harvey V; Mason B; Jeal PN
    Br J Cancer; 1990 Jan; 61(1):133-6. PubMed ID: 2297484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
    Hirshaut Y; Kesselheim H
    Cancer; 1983 Jun; 51(11):1998-2004. PubMed ID: 6687698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Cummings FJ; Gelman R; Horton J
    J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.